Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
US biopharmaceutical research companies are currently developing 180 new medicines to help the nearly 400 million people worldwide who suffer from diabetes, says a new industry report.
The medicines in development are all either in clinical trials or under review by the Food and Drug Administration (FDA), and they include 30 potential new treatments for type 1 diabetes, 100 for type 2 and 52 for diabetes-related conditions, according to the report, from the Pharmaceutical Research and Manufacturers of America (PhRMA).
Products in development include: - a medicine that improves glucose-dependent insulin secretion for type 2 diabetes; - a medicine designed to inhibit an enzyme linked to diabetic neuropathy; and - a treatment designed to stimulate and enhance the regeneration of insulin-producing cells for type 1 diabetes.
http://www.pharmatimes.com/Article/14-02-18/US_biopharma_180_new_diabetes_drugs_now_in_R_D.aspx
The medicines in development are all either in clinical trials or under review by the Food and Drug Administration (FDA), and they include 30 potential new treatments for type 1 diabetes, 100 for type 2 and 52 for diabetes-related conditions, according to the report, from the Pharmaceutical Research and Manufacturers of America (PhRMA).
Products in development include: - a medicine that improves glucose-dependent insulin secretion for type 2 diabetes; - a medicine designed to inhibit an enzyme linked to diabetic neuropathy; and - a treatment designed to stimulate and enhance the regeneration of insulin-producing cells for type 1 diabetes.
http://www.pharmatimes.com/Article/14-02-18/US_biopharma_180_new_diabetes_drugs_now_in_R_D.aspx